Phase1 study of immune-enhanced locoregional therapy: hepatic artery embolization combined with intra-tumoral and systemic poly-ICLC to treat liver cancer

Jon, Ali F.; Kisza, P.; Contractor, Sohail; Torre, Andrew de la

doi:10.1016/j.jvir.2016.12.988

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the patient eventually succumbed, his life was extended well beyond expectations 15 . A phase II trial of single-dose treatment of ultrasound guided IT Poly-ICLC followed by IM Poly-ICLC was found to be safe in patients with advanced primary or metastatic liver cancers, with evidence of regression of non-injected metastatic lesions as well as the targeted lesions 16,17 .…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial

Kyi

Roudko

Sabado

et al. 2018

Clinical Cancer Research

108

View full text Add to dashboard Cite

Polyinosinic-polycytidylic acid-poly-l-lysine carboxymethylcellulose (poly-ICLC), a synthetic double-stranded RNA complex, is a ligand for toll-like receptor-3 and MDA-5 that can activate immune cells, such as dendritic cells, and trigger natural killer cells to kill tumor cells. In this pilot study, eligible patients included those with recurrent metastatic disease in whom prior systemic therapy (head and neck squamous cell cancer and melanoma) failed. Patients received 2 treatment cycles, each cycle consisting of 1 mg poly-ICLC 3× weekly intratumorally (IT) for 2 weeks followed by intramuscular (IM) boosters biweekly for 7 weeks, with a 1-week rest period. Immune response was evaluated by immunohistochemistry (IHC) and RNA sequencing (RNA-seq) in tumor and blood. Two patients completed 2 cycles of IT treatments, and 1 achieved clinical benefit (stable disease, progression-free survival 6 months), whereas the remainder had progressive disease. Poly-ICLC was well tolerated, with principal side effects of fatigue and inflammation at injection site (

show abstract

Section: Introductionmentioning

confidence: 99%